Cargando…

EMBR-15. PRC2 COMPLEX ENFORCES NEURONAL LINEAGE AND SUPPRESSES TUMOR GROWTH IN SHH MEDULLOBLASTOMA

Hyperactivation of Sonic Hedgehog (SHH) signaling pathway drives tumor progression in the largest medulloblastoma subgroup. During cerebellar development, promoters of SHH target genes show inhibitory trimethylation of histone H3 at lysine 27 (H3K27me3), mediated by the Polycomb Repressive Complex 2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cleveland, Abigail, Malawsky, Daniel, Churiwal, Mehal, Gershon, Timothy
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Embryonal Tumors
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168086/ http://dx.doi.org/10.1093/neuonc/noab090.033

Ejemplares similares

EMBR-19. SHH-DRIVEN MEDULLOBLASTOMA WITH CONCURRENT UNILATERAL RENAL AGENESIS
por: Aaroe, Ashley, et al.
Publicado: (2021)

EMBR-33. YAP1 FUNCTION IN SHH MEDULLOBLASTOMA PROGRESSION AND IMMUNE EVASION
por: Abdelfattah, Nourhan, et al.
Publicado: (2021)

EMBR-27. NEOPLASTIC AND IMMUNE SINGLE CELL TRANSCRIPTOMICS DEFINE SUBGROUP-SPECIFIC INTRA-TUMORAL HETEROGENEITY OF CHILDHOOD MEDULLOBLASTOMA
por: Donson, Andrew, et al.
Publicado: (2021)

EMBR-18. LASER INTERSTITIAL THERMAL THERAPY FOR RECURRENT MEDULLOBLASTOMA
por: Xu, Jordan, et al.
Publicado: (2021)

EMBR-10. INOSITOL TREATMENT INHIBITS MEDULLOBLASTOMA THROUGH SUPPRESSION OF EPIGENETIC-DRIVEN METABOLIC ADAPTATION
por: Badodi, Sara, et al.
Publicado: (2021)

EMBR-07. MYC BUT NOT MYCN GENERATES AGGRESSIVE GROUP 3 MEDULLOBLASTOMA BY ARF PATHWAY SUPPRESSION
por: Mainwaring, Oliver, et al.
Publicado: (2021)

EMBR-20. ELONGATION CONTROL OF MRNA TRANSLATION DRIVES GROUP 3 MEDULLOBLASTOMA
por: Delaidelli, Alberto, et al.
Publicado: (2021)

EMBR-23. KIF11 DEPENDENCY ON P53 MUTATIONAL STATUS IN MEDULLOBLASTOMA
por: Huang, Shiying, et al.
Publicado: (2021)

EMBR-12. TARGETING THE RNA-BINDING PROTEIN LIN28B IN GROUP 3 MEDULLOBLASTOMA
por: Shahab, Shubin, et al.
Publicado: (2021)

EMBR-24. YB1 IS CRITICAL FOR MEDULLOBLASTOMA TUMOR MAINTENANCE AND DNA REPAIR FOLLOWING THERAPEUTIC INTERVENTION
por: McSwain, Leon, et al.
Publicado: (2021)

EMBR-22. RATIONAL DEVELOPMENT OF SYNERGISTIC THERAPIES ALONGSIDE BMI1 INHIBITION FOR GROUP 3 MEDULLOBLASTOMA
por: Bakhshinyan, David, et al.
Publicado: (2021)

EMBR-09. EXAMINING THE ROLE OF THE DEVELOPMENTALLY ENCODED TRANSCRIPTION FACTOR, LHX9, IN GROUP 3 MEDULLOBLASTOMA
por: Injac, Sarah, et al.
Publicado: (2021)

EMBR-32. INTEGRATED STRESS RESPONSE PLAYS A PRO-SURVIVAL ROLE IN MYC-DRIVEN MEDULLOBLASTOMA
por: Langman, Sofya, et al.
Publicado: (2021)

EMBR-01. CLASS I HDAC INHIBITORS AND PLK1 INHIBITORS SYNERGIZE IN MYC-AMPLIFIED MEDULLOBLASTOMA
por: Valinciute, Gintvile, et al.
Publicado: (2021)

EMBR-16. SMOOTHENED-ACTIVATING LIPIDS DRIVE RESISTANCE TO CDK4/6 INHIBITION IN HEDGEHOG-ASSOCIATED MEDULLOBLASTOMA
por: Daggubati, Vikas, et al.
Publicado: (2021)

EMBR-02. OLIG2 REPRESENTS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET IN MYC-AMPLIFIED MEDULLOBLASTOMA RELAPSE AND METASTASIS
por: Xu, Zhenhua, et al.
Publicado: (2021)

EMBR-06. EFFECTIVE INHIBITION OF MYC-AMPLIFIFIED GROUP 3 MEDULLOBLASTOMA BY FACT-TARGETED CURAXIN DRUG CBL0137
por: Wang, Jiajia, et al.
Publicado: (2021)

EMBR-14. INFLUENCE OF MRI FEATURES ON THE SURVIVAL AND IMPACT ON INDIVIDUAL MOLECULAR SUBGROUPS: RESULT FROM 171 PATIENTS WITH MEDULLOBLASTOMA
por: Dasgupta, Archya, et al.
Publicado: (2021)

EMBR-13. NOVEL SYNERGISTIC APPROACHES FOR TARGETED THERAPY OF MYC-DRIVEN MEDULLOBLASTOMA USING CRISPR/CAS9 GENE EDITING
por: Qin, Nan, et al.
Publicado: (2021)

EMBR-25. GENOME-WIDE GENETIC AND EPIGENETIC ASSESSMENT OF GROUP 4 MEDULLOBLASTOMA FOR IMPROVED, BIOMARKER DRIVEN, PROGNOSTICATION AND RISK-STRATIFICATION
por: Goddard, Jack, et al.
Publicado: (2021)

EMBR-21. CLINICALLY TRACTABLE OUTCOME PREDICTION OF GROUP 3/4 MEDULLOBLASTOMA BASED ON TPD52 IMMUNOHISTOCHEMISTRY: A MULTICOHORT STUDY
por: Delaidelli, Alberto, et al.
Publicado: (2021)

EMBR-28. CNS DISTRIBUTIONAL KINETICS OF PANOBINOSTAT IN THE MOUSE
por: Zhang, Wenqiu, et al.
Publicado: (2021)

EMBR-08. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON “HEAD START” 4 CLINICAL TRIAL
por: Dhall, Girish, et al.
Publicado: (2021)

EMBR-17. DE-INTENSIFICATION OF RADIOTHERAPY IN RIGOROUSLY DEFINED LOW-RISK WNT-SUBGROUP MEDULLOBLASTOMA IS ASSOCIATED WITH UNACCEPTABLY HIGH RISK OF NEURAXIAL FAILURE: RESULTS FROM THE PROSPECTIVE FOR-WNT STUDY
por: Gupta, Tejpal, et al.
Publicado: (2021)

EMBR-31. DEVELOPMENT OF INJECTABLE POLYSACCHARIDE HYDROGEL TO ENHANCE DRUG PENETRATION IN PEDIATRIC BRAIN TUMORS
por: Patel, Jenny, et al.
Publicado: (2021)

EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA
por: Hansford, Jordan, et al.
Publicado: (2021)

PRC2 disruption in cerebellar progenitors produces cerebellar hypoplasia and aberrant myoid differentiation without blocking medulloblastoma growth
por: Cleveland, Abigail H., et al.
Publicado: (2023)

EMBR-05. THE TENTATIVE APPLICATION OF EN BLOC CONCEPT IN THE PEDIATRIC BRAIN TUMOR: EXPERIENCE FROM A LARGE PEDIATRIC CENTER IN CHINA
por: Cao, Liangliang, et al.
Publicado: (2021)

scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy
por: Ocasio, Jennifer Karin, et al.
Publicado: (2019)

ETMR-15. USE OF HIGH-DOSE CHEMOTHERAPY FOR TWO CHILDREN WITH EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES
por: Kusano, Shimpei, et al.
Publicado: (2020)

Functional loss of a noncanonical BCOR–PRC1.1 complex accelerates SHH-driven medulloblastoma formation
por: Kutscher, Lena M., et al.
Publicado: (2020)

Author Correction: scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy
por: Ocasio, Jennifer Karin, et al.
Publicado: (2022)

The transcriptional landscape of Shh medulloblastoma
por: Skowron, Patryk, et al.
Publicado: (2021)

Evasion of cell senescence in SHH medulloblastoma
por: Tamayo-Orrego, Lukas, et al.
Publicado: (2016)

MDB-23. ELP1 GERMLINE DEFICIENCY SENSITIZES THE GRANULE NEURON LINEAGE TO SHH MEDULLOBLASTOMA AND EXPOSES NOVEL THERAPEUTIC VULNERABILITIES
por: Garcia-Lopez, Jesus, et al.
Publicado: (2023)

MBRS-08. SONIC HEDGEHOG SIGNALING PRIMES CEREBELLAR GRANULE NEURON PROGENITORS, THE CELL OF ORIGIN FOR MEDULLOBLASTOMA, FOR APOPTOSIS BY INDUCING PRO APOPTOTIC BIM
por: Cleveland, Abigail, et al.
Publicado: (2020)

ETMR-08. INTERNATIONAL CONSENSUS PROTOCOL FOR EMBRYONAL TUMOR WITH MULTILAYER ROSETTES
por: Hanson, Derek, et al.
Publicado: (2020)

ETMR-14. TREATMENT OF EMBRYONAL TUMOURS WITH MULTILAYERED ROSETTES (ETMR) WITH CARBOPLATIN-ETOPOSIDE INDUCTION AND TANDEM HIGH-DOSE CHEMOTHERAPY WITHIN THE PROSPECTIVE HIT-TRIALS AND REGISTRIES
por: Juhnke, Björn-Ole, et al.
Publicado: (2020)

ETMR-20. IMPACT OF HIGH DOSE CHEMOTHERAPY WITH AND WITHOUT METHOTREXATE (MTX) ON OUTCOME OF PATIENTS WITH EMBRYONAL TUMORS WITH MULTI-LAYERED ROSETTES (ETMRs): A REPORT FROM CHILDREN’S ONCOLOGY GROUP PHASE III TRIAL ACNS0334
por: Mazewski, Claire, et al.
Publicado: (2020)

ETMR-01. TREATMENT OUTCOME OF TWO CASES WITH HIGH-GRADE NEUROEPITHELIAL TUMOR WITH BCOR ALTERATION
por: Kristensen, Ines, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_39vjbd36s6qnet6e0kmm3vhjo9